Isomorphic Labs has raised $5 billion in a Series C funding round co-led by Greenoaks and Sequoia Capital, the Alphabet-backed AI drug discovery company said on Tuesday — money it plans to use to move its first therapeutic programs toward clinical trials. Why it matters: this is one of the largest single raises in AI drug discovery, and it lands only about six months after the company’s last round.
November 17, 2026
What happened?
Isomorphic Labs, which was spun out of Google DeepMind in 2021, announced a $5 billion Series C on Tuesday. The company declined to share its valuation. The round comes roughly six months after a $2.1 billion Series B led by Thrive Capital, meaning Isomorphic has now raised more than $7 billion across just those two rounds in about half a year.
Who invested?
Greenoaks and Sequoia Capital co-led the round. Andreessen Horowitz and other new investors joined, Alphabet made a significant investment, and existing backers including Thrive Capital, MGX and GV also participated. That mix — its parent Alphabet writing a large check alongside top-tier venture firms — signals that the funding is meant to carry the company from platform-building into the far more expensive work of testing drugs in people.
What is Isomorphic building?
The company’s core technology is the IsoDDE drug design engine, which uses AI to design new drugs, predict their properties and refine them before scientists decide which candidates to actually make and test. Founder and CEO Demis Hassabis said the round will let the company accelerate work on foundational biology models, deepen its understanding of systemic disease, and drive its first therapeutic programs toward clinical trials. Isomorphic says it has seen positive pre-clinical results in its internal oncology and immunology programs and in work with partners, setting the stage for clinical entry. The company lists Novartis, Eli Lilly and Johnson & Johnson as partners on its website.
Why it matters
AI drug discovery has produced plenty of models and very few medicines that have reached patients. Isomorphic is now explicitly spending to cross that gap: clinical trials are where AI-designed candidates either prove the approach works in humans or join the long list of promising pre-clinical results that went nowhere. A $5 billion war chest, raised at speed on top of a $2.1 billion round, also raises the bar for every rival in the field — few can match that pace of spending. Our take: watch the first clinical-entry announcements. That, not the fundraising total, is the milestone that tells you whether the engine produces drugs or just candidates. Everything AI, tested — and in this case, eventually tested in trials.
Frequently asked questions
How much did Isomorphic Labs raise?
$5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, announced on Tuesday, November 17, 2026. The company declined to share its valuation.
What will Isomorphic do with the money?
According to founder and CEO Demis Hassabis, the round will accelerate work on foundational biology models and systemic disease understanding, and drive the company’s first therapeutic programs toward clinical trials.
Who are Isomorphic Labs’ partners?
The company lists Novartis, Eli Lilly and Johnson & Johnson as partners on its website, and says it has seen positive pre-clinical results in internal oncology and immunology programs and with partners.
Sources: Reuters

